阿来替尼治疗ALK基因融合重排NSCLC脑转移瘤的临床疗效分析

Efficacy of alectinib for ALK-positive NSCLC brain metastases

目的:探讨阿来替尼治疗ALK融合重排非小细胞肺癌(non-small cell lung cance,NSCLC)脑转移患者的疗效及不良反应。方法:回顾性分析2016年8月至2019年10月天津医科大学肿瘤医院34例以脑转移为首发的ALK基因融合重排NSCLC患者的临床资料,其中13例(38.2%)患者接受阿来替尼单药一线治疗。男性7例(53.8%),女性6例(46.2%),中位年龄51(35~72)岁。应用Kaplan-Meier分析其生存情况。结果:阿来替尼治疗ALK基因融合重排肺癌脑转移瘤,颅内中位无进展生存期(median pro-gression-free survival,m PFS)为24.5个月。药物不良反应较轻。结论:在颅内可测量病灶得到局部治疗的基础上,阿来替尼作为ALK基因融合重排NSCLC脑转移患者的一线治疗方案,显著延长患者无进展生存期(progression-free survival,PFS)。

Objective: To investigate the effect of alectinib in the treatment of brain metastases from anaplastic lymphoma kinase(ALK)-positive non-small cell lung cancer(NSCLC). Methods: Thirty-four cases of ALK-positive NSCLC in Tianjin Medical University Cancer Institute and Hospital, between August 2016 to October 2019, were retrospectively analyzed. Thirteen cases received first-line single drug therapy(600 mg PO bid) of Alectinib. 7 cases(53.8%) were male, 6 cases were female(46.2%), the median age was 51(35-72).The Kaplan-Meier method was used to examine progression-free survival(PFS). Results: The median progression-free survival(mPFS)of the alectinib group was 24.5 months, and the adverse drug reactions were mild. Conclusions: The use of alectinibas first-line treatment after the local treatment of measurable intracranial lesions significantly increased the PFS of patients with brain metastases from ALK-positive NSCLC.